Evaluation of Progression-Free Survival and Overall Survival of Epidermal Growth Factor Receptor-Positive Metastatic Lung Adenocarcinoma Patients Treated with Erlotinib

Background: Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) such as erlotinib and gefitinib have shown promising efficacy and tolerability in patients with advanced NSCLC. Identifying subgroups of patients who benefit from EGFR-TKI treatment may help achieve better treatment...

Descripción completa

Detalles Bibliográficos
Autores principales: Shahriari, Saeedeh, Seifi, Sharareh, Khodakarim, Nastaran, Ramim, Tayeb, Dashtpeima, Alireza
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Iran University of Medical Sciences 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9448506/
https://www.ncbi.nlm.nih.gov/pubmed/36128277
http://dx.doi.org/10.47176/mjiri.36.31

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9448506/
https://www.ncbi.nlm.nih.gov/pubmed/36128277
http://dx.doi.org/10.47176/mjiri.36.31

Ejemplares similares